Reduce the risk of death! The results of dagre Net III DAPA-HF results are updated.

On March 28th AstraZeneff released the latest data from the Phase III DAPA-HF study subgroup analysis, showing that, compared to placebos, Dagli net reduced the incidence of heart failure exacerbation or cardiovascular death in patients with reduced blood cell score, regardless of background therapy.
effects were evaluated in patients with HFrEF who received a wide range of medications, device therapy, and cardiac resynchronization, and the results showed that a decrease in the incidence of major compound endpoints was observed in these subgroups.
heart failure (HF) affects about 64 million people worldwide and is the leading cause of hospitalization among people over 65.
it is estimated that half of heart failure patients die within five years of diagnosis, comparable to the fatality rates of the most common cancers in men (prostate and bladder cancer) and women (breast cancer).
Pangalos, Executive Vice President of Biopharmaceutical Research and Development at AstraZenewan, said, "The latest data from the DAPA-HF study further enhance dagli's net clinical outcomes outside of diabetic patients.
regardless of the background therapy, Daglie net reduces the risk of worsening heart failure, which makes dagli net potentially improves current levels of care and reduces the burden of heart failure in patients worldwide.
said the findings were presented at the American College of Cardiology's 69th annual scientific meeting and the World Congress of Cardiology (ACC.20/WCC) and published in The European Heart Journal.
, approved by the FDA in 2014/1/8, has now been approved for two indications in the United States: type 2 diabetes, and 2) reducing the risk of hospitalization for patients with type 2 diabetes or other cardiovascular deaths.
FDA has accepted a new application for a supplementary drug in January 2020 to reduce the risk of cardiovascular-caused death or heart failure in patients with HFrEF, and has granted it priority review status, which is expected to be approved in 2020Q2 (see: Dagre Net Heart Failure Adaptation Listing Application Is FDA Priority Review).
.